Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 23657159)

1.

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.

Filppula AM, Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2013 Sep;94(3):383-93. doi: 10.1038/clpt.2013.92. Epub 2013 May 8.

PMID:
23657159
2.

Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.

Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2013 Jan;41(1):50-9. doi: 10.1124/dmd.112.048017. Epub 2012 Oct 1.

3.

The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.

Tornio A, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2006 Aug;62(8):645-51. Epub 2006 Jul 11.

PMID:
16832679
4.

CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.

Karonen T, Neuvonen PJ, Backman JT.

Br J Clin Pharmacol. 2012 Feb;73(2):257-67. doi: 10.1111/j.1365-2125.2011.04086.x.

5.

Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.

Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2010 Aug;88(2):223-30. doi: 10.1038/clpt.2010.73. Epub 2010 Jun 30.

PMID:
20592724
6.

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ.

Drug Metab Dispos. 2009 Dec;37(12):2359-66. doi: 10.1124/dmd.109.029728. Epub 2009 Sep 22.

7.

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.

Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2006 Jun;62(6):463-72. Epub 2006 Apr 27.

PMID:
16758263
8.

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.

Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ.

Clin Pharmacol Ther. 2005 May;77(5):404-14.

PMID:
15900286
9.

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS.

Br J Clin Pharmacol. 2013 Jan;75(1):217-26. doi: 10.1111/j.1365-2125.2012.04343.x.

10.

Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.

Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ.

Br J Clin Pharmacol. 2005 Aug;60(2):208-17.

11.

Effect of St John's wort on imatinib mesylate pharmacokinetics.

Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ.

Clin Pharmacol Ther. 2004 Oct;76(4):323-9.

PMID:
15470331
12.

Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2012 May;91(5):846-55. doi: 10.1038/clpt.2011.313.

PMID:
22472994
13.

Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2011 Apr;89(4):579-86. doi: 10.1038/clpt.2010.358. Epub 2011 Mar 2.

PMID:
21368757
14.

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.

Tornio A, Niemi M, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2007 May;63(5):463-9. Epub 2007 Feb 27.

PMID:
17333159
15.

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.

Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M.

Cancer Chemother Pharmacol. 2004 Feb;53(2):102-6. Epub 2003 Nov 7.

PMID:
14605865
16.

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.

Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ.

Clin Pharmacol Ther. 2006 Mar;79(3):231-42. Epub 2006 Feb 7.

PMID:
16513447
17.

Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.

Ostrowicz A, Mikołajczak PL, Wierzbicka M, Boguradzki P.

Acta Pol Pharm. 2014 Sep-Oct;71(5):843-54.

18.

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT.

Drug Metab Dispos. 2011 Oct;39(10):1977-86. doi: 10.1124/dmd.111.040931. Epub 2011 Jul 21.

19.

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.

Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR.

Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31.

20.

Effect of antacid on imatinib absorption.

Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH.

Cancer Chemother Pharmacol. 2009 Feb;63(3):525-8. doi: 10.1007/s00280-008-0778-7. Epub 2008 May 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk